Onychomycosis: a compendium of facts and a clinical experience.
Fifty percent of all nail disturbances result from onychomycosis, with toenails being affected approximately four times as often as those of the fingernails. The overall incidence in the population is not known, but it is reported at about 2%-13% and is presently on the rise. This lengthy paper reviews all facets of onychomycosis. The present-day classification of onychomycosis is presented. Predisposing factors, causative organisms, as well as the differential diagnosis are included. A thorough comparison of the five presently available oral antifungal agents (griseofulvin, ketoconazole, itraconazole, terbinafine, and fluconazole) in an easy-to-read table is presented. A second table presents many studies performed by many researchers in various countries on these same drugs. The author has included her own personal clinical experience using both fluconazole and terbinafine in 22 and 51 patients with pedal onychomycosis, respectively. This is not meant to be a "controlled study," but rather the experience of one podiatrist in an office setting. The newer oral antifungal agents (itraconazole, terbinafine, and fluconazole) are highly recommended even for the most severe cases of onychomycosis.
Schlefman
B S
BS
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D005534:Foot Diseases / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D014009:Onychomycosis / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome
D000935:Antifungal Agents